NZ598459A - Adjuvant comprising aluminium, oligonucleotide and polycation - Google Patents

Adjuvant comprising aluminium, oligonucleotide and polycation

Info

Publication number
NZ598459A
NZ598459A NZ598459A NZ59845910A NZ598459A NZ 598459 A NZ598459 A NZ 598459A NZ 598459 A NZ598459 A NZ 598459A NZ 59845910 A NZ59845910 A NZ 59845910A NZ 598459 A NZ598459 A NZ 598459A
Authority
NZ
New Zealand
Prior art keywords
oligonucleotide
lys
adjuvant
aluminium
polycation
Prior art date
Application number
NZ598459A
Other languages
English (en)
Inventor
Rino Rappuoli
Derek O’Hagan
Michele Pallaoro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ598459A publication Critical patent/NZ598459A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NZ598459A 2009-08-27 2010-08-27 Adjuvant comprising aluminium, oligonucleotide and polycation NZ598459A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23759509P 2009-08-27 2009-08-27
PCT/IB2010/002259 WO2011024071A1 (en) 2009-08-27 2010-08-27 Adjuvant comprising aluminium, oligonucleotide and polycation

Publications (1)

Publication Number Publication Date
NZ598459A true NZ598459A (en) 2014-03-28

Family

ID=43428549

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598459A NZ598459A (en) 2009-08-27 2010-08-27 Adjuvant comprising aluminium, oligonucleotide and polycation

Country Status (9)

Country Link
US (1) US8858958B2 (enExample)
EP (1) EP2470205A1 (enExample)
JP (2) JP2013503148A (enExample)
CN (1) CN102740882A (enExample)
AU (1) AU2010288239B2 (enExample)
BR (1) BR112012004276A2 (enExample)
CA (1) CA2772103A1 (enExample)
NZ (1) NZ598459A (enExample)
WO (1) WO2011024071A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591768A (en) * 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
CN104736563A (zh) 2012-07-27 2015-06-24 国家健康与医学研究院 Cd147作为受体用于脑膜炎球菌至血管内皮的菌毛介导的粘附
JP6700512B2 (ja) * 2014-08-04 2020-05-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１由来ペプチドおよびそれを含むワクチン
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂系统及制备该佐剂的方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6165774A (en) * 1995-09-22 2000-12-26 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
EP0909323B1 (en) 1996-01-04 2007-02-28 Novartis Vaccines and Diagnostics, Inc. Helicobacter pylori bacterioferritin
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7701098A (en) 1997-05-28 1998-12-30 Michael A. Apicella Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
DE69738472T2 (de) 1997-08-21 2009-01-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
PT1127137E (pt) 1998-11-03 2007-12-28 Staat Nl Verteg Door Min Welzi Lps com toxicidade reduzida a partir de bactérias gramnegativas modificadas geneticamente
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
ATE460484T1 (de) 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
ES2588917T3 (es) 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
AU2818101A (en) 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ES2386386T3 (es) 2001-12-12 2012-08-20 Novartis Vaccines And Diagnostics S.R.L. Inmunización contra Chlamydia trachomatis
DE60325696D1 (de) 2002-02-22 2009-02-26 Ca Nat Research Council Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2351579B1 (en) * 2002-10-11 2016-09-21 Novartis Vaccines and Diagnostics S.r.l. Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
ES2351489T3 (es) * 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
WO2005002619A2 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
WO2005084306A2 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
AU2006259858A1 (en) 2005-05-12 2006-12-28 Novartis Vaccines And Diagnostics S.R.L. Immunogenic compositions for Chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007110700A2 (en) 2005-12-22 2007-10-04 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
WO2007071786A2 (en) * 2005-12-23 2007-06-28 Glaxosmithkline Biologicals Sa Conjugate vaccines
ES2337309T5 (es) 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
CA2706617A1 (en) * 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
EP2235532B1 (en) 2007-12-24 2013-04-24 Novartis AG Assays for adsorbed influenza vaccines
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
ITMI20081249A1 (it) 2008-07-09 2010-01-09 Novartis Vaccines & Diagnostic Immunogeni di escherichia coli con solubilità migliorata.
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations

Also Published As

Publication number Publication date
US20110052716A1 (en) 2011-03-03
WO2011024071A8 (en) 2012-04-26
US8858958B2 (en) 2014-10-14
CA2772103A1 (en) 2011-03-03
JP2013503148A (ja) 2013-01-31
CN102740882A (zh) 2012-10-17
EP2470205A1 (en) 2012-07-04
BR112012004276A2 (pt) 2017-10-24
JP2016034980A (ja) 2016-03-17
WO2011024071A1 (en) 2011-03-03
AU2010288239B2 (en) 2014-01-16
AU2010288239A1 (en) 2012-03-22
WO2011024071A9 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
EP2562183A8 (en) Novel immunogenic epitopes for immunotherapy
NZ597858A (en) Vaccines and compositions against streptococcus pneumoniae
DK2566507T3 (da) Biokonjugatvacciner med kapselformige grampositive bakterier
NZ591925A (en) Adjuvant composition comprising a host defense peptide, an immunostimulatory sequence and a polyanionic polymer
NZ620441A (en) Pcsk9 vaccine
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2009089535A3 (en) Polypeptide vaccine and vaccination strategy against mycobacterium
MX377650B (es) Vacuna y métodos para reducir una infección por campylobacter.
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
MX343111B (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus.
WO2000056360A3 (en) Vaccine against antigens from bacteriae
WO2013082535A3 (en) Controlled-release peptide compositions and uses thereof
EP2759307A3 (en) Vaccine against Streptococci
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
WO2007116409A8 (en) Improved vaccines comprising multimeric hsp60 peptide carriers
SG178904A1 (en) Combination vaccines against respiratory tract diseases
WO2009135199A3 (en) Vaccine compositions and methods
JP2016106117A5 (enExample)
CA3010977A1 (en) Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
NZ603854A (en) West nile virus vaccine
WO2009072555A1 (ja) 癌ワクチン
WO2013171661A3 (en) Adjuvant formulations and methods
WO2013012875A3 (en) Bacterial rnas as vaccine adjuvants

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20140409

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 AUG 2017 BY CPA GLOBAL

Effective date: 20140710

LAPS Patent lapsed